share_log

Intra-Cellular Therapies Shares Are Trading Sharply Higher After Johnson & Johnson Agreed to Acquire the Company for $132.00 per Share in Cash.

Intra-Cellular Therapies Shares Are Trading Sharply Higher After Johnson & Johnson Agreed to Acquire the Company for $132.00 per Share in Cash.

Intra-Cellular Therapies的股價在強生同意以每股132.00美元現金收購該公司後大幅上漲。
Benzinga ·  01/13 11:35

Intra-Cellular Therapies Shares Are Trading Sharply Higher After Johnson & Johnson Agreed to Acquire the Company for $132.00 per Share in Cash.

Intra-Cellular Therapies的股價在強生同意以每股132.00美元現金收購該公司後大幅上漲。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 374

熱點推薦

搶先評論

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。